Psychopharmacological interaction of alcohol and posttraumatic stress disorder: Effective action of naringin

European Journal of Pharmacology, Journal Year: 2024, Volume and Issue: 978, P. 176791 - 176791

Published: June 27, 2024

Language: Английский

---

Alcohol in Daily Products: Health Risks, Cultural Considerations, and Economic Impacts

Risk Management and Healthcare Policy, Journal Year: 2025, Volume and Issue: Volume 18, P. 217 - 237

Published: Jan. 1, 2025

Ethanol, a bioactive compound prevalent in both social and industrial applications, is present alcoholic beverages as well range of everyday products. In food, ethanol functions primarily an additive or by-product fermentation, while pharmaceuticals cosmetics, it serves solvent preservative. Despite its widespread use, three critical research gaps exist current literature. First, existing focuses predominantly on single-sector analyses, overlooking the cumulative effects cross-sectoral exposure. Second, despite growing global market integration, there limited understanding how cultural religious requirements influence ethanol-related regulations product formulations. Third, economic models fail to integrate health impact costs compliance expenses, hindering effective policy development. The World Health Organization has determined that no amount alcohol consumption can be considered entirely safe, ethanol's impacts include contributions chronic diseases, neurotoxicity, potential carcinogenic effects. These risks are compounded by pervasive often unrecognized presence various products, particularly affecting vulnerable populations. burden associated with alcohol-related issues, including lost productivity healthcare costs, highlights necessity for robust public strategies stringent regulatory guidelines. This review investigates role across multiple domains, emphasizing medicine, evaluates broader implications health, practices, impact. recommend implementing standardized labeling systems, establishing cultural-sensitive alternatives formulations, developing harmonized international guidelines use industries.

Language: Английский

---

The TMEM132B-GABAA receptor complex controls alcohol actions in the brain

Cell, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Language: Английский

---

Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder

Frontiers in Psychiatry, Journal Year: 2024, Volume and Issue: 15

Published: June 11, 2024

Resistance to traditional treatment methods is still a major obstacle in modern psychiatry. As result, several studies are currently being conducted find effective alternatives therapies. One of these psilocybin, psychedelic substance that has been tested clinical trials as an adjunct psychotherapy. These focus on patients with depressive disorder (MDD), obsessive-compulsive (OCD) and use (SUD), particularly alcohol nicotine dependence. This article looks at the current understanding including data from conducted, psilocybin’s mechanism action, its safety level risk associated it.

Language: Английский

---

Phytoceutical Isoquercitrin and Ethanolic Extracts from Pequi (Caryocar coriaceum Wittm) Reverse Alcohol Withdrawal-Induced Anxiety in Adult Zebrafish (Danio rerio)

Behavioural Brain Research, Journal Year: 2025, Volume and Issue: unknown, P. 115439 - 115439

Published: Jan. 1, 2025

Language: Английский

---

Association Between GABRG2 and Self-Rating of the Effects of Alcohol in a French Young Adult Sample

Risk Management and Healthcare Policy, Journal Year: 2025, Volume and Issue: Volume 18, P. 291 - 304

Published: Jan. 1, 2025

Alcohol use is a leading risk factor for preventable death, injury, and disease globally. Low sensitivity to the effects of alcohol influenced by genes predicts harmful disorder (AUD). induces partly modulation gamma-aminobutyric acid receptors type A (GABAARs). This study investigates relationship between genetic variation in GABAAR subunit individual among French university students. The involved 1,409 students (34.5% women; mean age 20.3 years). was measured Self-Rating Effects Scale (SRE). SRE-scores from initial drinking, regular heavy drinking were investigated correlations with consumption associations single nucleotide polymorphisms (SNPs) (GABRA2, GABRG2, GABRA6). We replicated low high consumption. further found an association minor allele rs211014 (GABRG2) higher SRE-scores, linked dizziness motor incoordination. Genetic GABRG2 has previously been associated processes involving coordination (alcohol withdrawal, febrile- epileptic seizures). results our suggest that may influence sensitivity, which could inform strategies assessing AUD.

Language: Английский

---

Excessive Alcohol Use as a Risk Factor for Alzheimer’s Disease: Epidemiological and Preclinical Evidence

Advances in experimental medicine and biology, Journal Year: 2025, Volume and Issue: unknown, P. 211 - 242

Published: Jan. 1, 2025

Language: Английский

---

Baseline gut microbiome and metabolites are correlated with changes in alcohol consumption in participants in a randomized Zonisamide clinical trial

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: March 26, 2025

Development and severity of alcohol use disorder (AUD) has been linked to variations in gut microbiota their associated metabolites both animal human studies. However, the involvement microbiome consumption individuals with AUD undergoing treatment remains unclear. To address this, stool samples (n = 32) were collected at screening (baseline) trial completion from a double-blind, placebo-controlled zonisamide AUD. Alcohol was measured baseline endpoint 16-week period. Fecal analyzed via 16 S rRNA sequencing metabolome untargeted LC-MS. Both sex (p 0.003) psychotropic medication usage 0.025) are composition. The relative abundance 11 genera correlated percent drinking reduction (p.adj < 0.1). Overall community structure differed between high low reducers (67–100% 0–33% reduction, respectively; p 0.034). A positive relationship fecal GABA levels (R 0.43, p.adj 0.07) identified by function prediction confirmed ELISA metabolomics. Metabolomics analysis also found 3-hydroxykynurenine, neurotoxic intermediate metabolite tryptophan, negatively 0.047), over-represented reducers. These findings highlight importance amino acid participants treatment. It may hold significant value as predictive tool clinical settings better personalize intervention improve future.

Language: Английский

---

Association of acamprosate versus gabapentinoids with hospitalization and total mortality in alcohol use disorder

Journal of Hospital Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: March 27, 2025

Alcohol use disorder (AUD) significantly increases hospitalizations and death. US Food Drug Administration (FDA)-approved medications for AUD are underutilized. Gabapentinoids not FDA-approved but frequently prescribed by physicians. To examine the association of acamprosate gabapentinoids on healthcare utilization total mortality in patients with AUD. Two propensity score (PS)-matched retrospective cohort studies. Veterans diagnosed (years 2003-2021) initiating or an AUD-related encounter chronic opioid therapy (AUD-cohort). Another PS-cohort veterans who were hospitalized diagnoses (AUD-admission cohort). Subgroup analysis included people obstructive lung diseases, use, age categories. Co-primary outcomes admission alcohol withdrawal (AW-admission) annual rate acute care events. Secondary outcome was mortality. We matched 16,072 pairs gabapentinoid users AUD-cohort. AW-admission occurred 35.4% 30.0% (odds ratio [OR]: 1.28, 95% confidence interval [95% CI]: 1.22-1.34). Annual events 1.84 1.64, respectively (coefficient regression [β]: 0.20, CI: 0.12-0.28). There no difference (hazard ratio: 0.96, 0.91-1.005). In subgroup analysis, associated less subgroups using opioids older than 60 years. reduced lower rates compared to acamprosate. may offer a viable alternative carefully selected populations.

Language: Английский

---

Evaluating the efficacy of valproic acid in alcohol use disorder: a systematic analysis of clinical trials from ClinicalTrials.gov

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: April 25, 2025

Alcohol use disorder (AUD) represents a significant global health burden, characterized by high relapse rates and limited treatment options. Valproic acid, primarily used as an anticonvulsant mood stabilizer, has been suggested potential therapeutic agent for AUD, particularly in patients with coexisting psychiatric conditions. This study systematically analyses clinical trials from ClinicalTrials.gov to evaluate the efficacy of valproic acid treating AUD. A systematic search was conducted identify involving management substance (SUD). total 3,822 studies related SUD were initially identified. Screening narrowed this 96 trials, four completed specifically AUD included final analysis. Key outcomes rates, reduction, stabilization, withdrawal symptoms examined. The focused on various conditions, including alcohol dependence, bipolar abuse, traumatic brain injury use, medication-overuse headache. demonstrated benefits reducing consumption, stabilizing mood, managing specific subpopulations. However, remained some indicating long-term efficacy. Secondary showed improvements symptoms, though adverse effects such sedation gastrointestinal disturbances noted. shows option individuals conditions or complex profiles. While drug overall impact abstinence remains uncertain. Further research is needed better define role patient populations that may benefit most its use.

Language: Английский

---